Well-controlled comparative study of the clinical effectiveness of intravenous mexiletine and procainamide on ventricular premature contraction.
In a well-controlled study the clinical efficacy of a single intravenous injection of mexiletine (3 mg/Kg) on ventricular premature contractions was compared with that of procainamide (10 mg/Kg) using continuous electrocardiographic recordings. Of the 56 subjects studied, 55 were analyzed. These consisted of 28 cases in the mexiletine group and 27 in the procainamide group. The backgrounds of both groups were considered to be equivalent. Effectiveness on VPC ("marked and moderate improvement", as judged by the subcommittee) was seen in 88% of the mexiletine group and 84.6% of the procainamide group. This difference was not significant. The duration of efficacy was almost the same in the 2 groups. Overall improvement was the same as improvement in VPC. No significant difference was observed in the incidence of side effects. Five patients in the mexiletine group and 3 in the procainamide group reported side effects. The main side effect was light-headedness in the mexiletine group and a decrease in blood pressure in the procainamide group. A decrease in blood pressure was observed in 1 case in the mexiletine group but this was restored by an intravenous infusion of noradrenaline. Mexiletine had little effect on blood pressure, while procainamide induced a drop in the systolic pressure. This difference was significant. Overall utility ("markedly and moderately useful", as judged by the subcommittee) was seen in 84.0% of the mexiletine group and 84.6% of the procainamide group. There was no significant difference between the 2 groups. From the above results, it is concluded that mexiletine (3 mg/Kg) is as efficacious as procainamide (10 mg/Kg) in the treatment of VPC but that, unlike procainamide, mexiletine has little effect on blood pressure.